Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Licenses Dutch Biotech’s ADC Technology
August 6, 2021
- Ono Collaborates with UK’s AI Specialty Pharma on Drug Discovery
August 6, 2021
- Daiichi Sankyo Gets Rights to HISHOH's Immunostimulating Agent for Sublingual Immunotherapies
August 5, 2021
- Canaglu Filed for CKD in Type 2 Diabetes: Mitsubishi Tanabe
August 5, 2021
- Mitsubishi Tanabe’s Spinal Cord Injury Drug Gets Fast-Track Tag in US
August 5, 2021
- Mitsubishi Tanabe Yields 3.9% Sales Increase in Q1 on Radicava’s Overseas Growth
August 5, 2021
- Eisai’s Q1 Sales Jump 20% on Growth of 4 Global Brands
August 5, 2021
- Kyowa Kirin’s H1 Sales Grow 4.6% on Brisk Global Products
August 4, 2021
- Kyosomirai, Nissin Roll Out Cymbalta Generics
August 4, 2021
- Eisai’s Antiepileptic Med Fycompa Scores Label Expansions in China
August 4, 2021
- Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
August 3, 2021
- Chugai Launches Blood-Based Comprehensive Genomic Profiling Test for Solid Tumors
August 3, 2021
- AstraZeneca to Start e-Labeling, Will Complete Process for All Products by 2022-End
August 3, 2021
- Viatris Takes Over Celecox, Lipitor MAs in Japan
August 3, 2021
- MSD Renews Warning for Fainting after Gardasil Vaccination
August 3, 2021
- Takeda to Challenge Irish Authorities’ Break Fee Tax Assessment
August 3, 2021
- Kowa Recalls All Lots of Livalo OD Tablets 1 mg over Purity Test Results
August 3, 2021
- Astellas Hooks Up with Israeli Firm for Mitochondrial Cell Therapy Programs
August 3, 2021
- Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2
August 3, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…